NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/03/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization857.31 mln
Float123 mln
Earnings Date11/11/2026
EPS
0.83
Decent
P / E
5.25
Undervalued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
31.08
Highly suspicious
1-Year Forecast
5.19
Attractive
Relative Strength
29
/ 100
Underperforming
Business Description
Arbutus Biopharma is a clinical-stage company based in Warminster, Pennsylvania, focused on developing new treatments for chronic Hepatitis B. Its two lead drug candidates work in complementary ways ? one reduces harmful viral proteins in the body, while the other helps the immune system recognize and fight the infection. The company also holds a licensing agreement with Alnylam Pharmaceuticals to use their drug delivery technology in developing its products.
